Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 116Other hematologic neoplasm 80Myeloid 36Plasma cell 31Classical hematology 11Dermatologic 7Genitourinary 4CNS 4Gastrointestinal 3Thoracic 2Sarcoma 2Other neoplasm 2Gynecologic 2Breast 2Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Ovarian Neoplasms 14Lung Neoplasms 12Melanoma 11Colorectal Neoplasms 9Breast Neoplasms 9Stomach Neoplasms 7Pancreatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Neoplasm Metastasis 6Mesothelioma 6Carcinoma, Merkel Cell 5Small Cell Lung Carcinoma 4Multiple Myeloma 4Mesothelioma, Malignant 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Urogenital Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Liver Neoplasms 3Cholangiocarcinoma 3Carcinoma, Squamous Cell 3Thymoma 2

Interventions

pembrolizumab 8Nivolumab 6Gemcitabine 5spartalizumab 3Magnetic Resonance Spectroscopy 3Cyclophosphamide 3Azacitidine 3toripalimab 2fludarabine 2epacadostat 2atezolizumab 2Therapeutics 2Sirolimus 2Paclitaxel 2Interleukin-2 2Epoetin Alfa 2Cisplatin 2Bevacizumab 2vocimagene amiretrorepvec 1vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1temsirolimus 1sargramostim 1sapanisertib 1ruxolitinib 1rucaparib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × fludarabine × Thoracic × Clear all
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡